Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ

About

Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	1.34
Market Cap (Mil.):	$298.20
Shares Outstanding (Mil.):	24.38
Dividend:	--
Yield (%):	--

Financials

	SUPN.OQ	Industry	Sector
P/E (TTM):	--	49.13	43.38
EPS (TTM):	-1.10	--	--
ROI:	--	10.38	9.53
ROE:	--	11.64	11.11

Latest News about SUPN.OQ

Supernus epilepsy drug gets FDA nod, shares soar

- Supernus Pharmaceuticals Inc said the U.S. Food and Drug Administration granted a tentative approval to its generic epilepsy treatment Trokendi XR, sending its shares up as much as 164 percent.

26 Jun 2012

» More SUPN.OQ News

Earnings vs Estimates

Analyst Research Reports

Report Title	Price
Supernus Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
SUPERNUS PHARMA (SUPN) Zacks Company Snapshot Provider: Zacks Investment Research Inc.	$12.00 Buy
SUPERNUS PHARMA (SUPN) Zacks Company Snapshot Provider: Zacks Investment Research Inc.	$12.00 Buy
Supernus Pharmaceuticals, Inc. - Strategic SWOT Analysis Review Provider: GlobalData	$219.00 Buy
Supernus Pharmaceuticals, Inc. - Product Pipeline Review Provider: GlobalData	$230.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Africa
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.